Drug Sales Trends for ILEVRO

Annual Sales Revenues and Units Sold for ILEVRO

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
ILEVRO			2021
ILEVRO			2020
ILEVRO			2019
ILEVRO			2018
ILEVRO			2017
ILEVRO			2016
ILEVRO			2015

Market Analysis and Sales Projections for ILEVRO

Overview of ILEVRO

ILEVRO, also known as nepafenac ophthalmic suspension 0.3%, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation following cataract surgery. It is part of the broader ophthalmic drugs market, which is experiencing significant growth driven by increasing prevalence of eye disorders and advancements in healthcare infrastructure.

Market Size and Growth

The global ophthalmic drugs market, within which ILEVRO operates, is projected to grow substantially. Here are some key statistics:

• The global ophthalmic drugs market is expected to reach USD 67.1 billion by 2030, growing at a CAGR of 7.40% from 2022 to 2030[1].
• In the U.S., the ophthalmic drugs market was valued at USD 16.11 billion in 2023 and is projected to reach USD 33.51 billion by 2033, growing at a CAGR of 7.6% during the forecast period[3].

Segment Insights

Drug Class

ILEVRO falls under the NSAID segment, but its market performance is closely tied to the broader anti-inflammatory and anti-VEGF agents segments. Here are some insights:

• Anti-VEGF agents, which are closely related in terms of therapeutic application, held a dominant revenue share of 32.5% in 2021 globally and 32.8% in the U.S. in 2023. This segment is driven by the rising demand for treatments of retinal disorders such as age-related macular degeneration (AMD) and diabetic retinopathy[1][3].

Disease Insights

ILEVRO is specifically used for post-cataract surgery pain and inflammation, but its market is influenced by the overall prevalence of eye diseases:

• Retinal disorders, including conditions like AMD and diabetic retinopathy, dominated the market with a revenue share of 35.8% globally in 2021 and 36.7% in the U.S. in 2023. This segment is expected to continue growing due to the increasing aging population and rising incidence of these conditions[1][4].

Route of Administration and Dosage Form

ILEVRO is administered topically as an eye drop, which is a preferred route due to its targeted delivery and ease of use:

• The topical route of administration dominated the ophthalmic drugs market in 2021, and the eye drops segment is expected to hold the largest share due to high patient compliance and the availability of over-the-counter (OTC) products[1].

Sales Projections

While specific sales projections for ILEVRO are not provided in the sources, we can infer its potential performance based on the broader market trends:

• Company Performance: Harrow Health Inc., which has commercialized ILEVRO in the U.S., has seen significant activity in the ophthalmic market. For instance, in June 2022, Harrow Health Inc announced that MAXITROL and IOPIDINE 1% are commercially available in the U.S., indicating a strong presence in the market[1].
• Market Growth: Given the growing demand for ophthalmic drugs, particularly for post-surgical care, ILEVRO is likely to benefit from the overall market expansion. The U.S. ophthalmic drugs market's growth at a CAGR of 7.6% from 2024 to 2033 suggests a favorable environment for products like ILEVRO[3].

Competitive Landscape

ILEVRO operates in a competitive market with several key players:

• Companies like Alcon, Pfizer Inc., and Bausch + Lomb are major players in the ophthalmic drugs market. The competitive landscape is driven by innovation, with companies focusing on developing long-term therapies and securing regulatory approvals for new products[1][4].

Regulatory and Clinical Developments

Recent developments in the regulatory and clinical space are crucial for ILEVRO's market position:

• In May 2023, Harrow Health Inc released several ophthalmic drugs, including ILEVRO, in the U.S. market. Such releases and ongoing clinical trials, such as the planned dry eye chamber clinical trial, indicate a proactive approach to market expansion and product development[3][4].

Key Takeaways

• Market Growth: The ophthalmic drugs market is expected to grow significantly, driven by the increasing prevalence of eye disorders and advancements in healthcare.
• Segment Dominance: Anti-VEGF agents and retinal disorders segments are dominant and growing, influencing the market for products like ILEVRO.
• Route of Administration: Topical administration, particularly eye drops, remains a preferred and growing segment.
• Competitive Landscape: The market is competitive with major players focusing on innovation and regulatory approvals.
• Regulatory Developments: Recent releases and ongoing clinical trials are key to ILEVRO's market performance.

FAQs

1. What is ILEVRO used for? ILEVRO (nepafenac ophthalmic suspension 0.3%) is used to treat pain and inflammation following cataract surgery.

2. What is the projected growth rate of the global ophthalmic drugs market? The global ophthalmic drugs market is expected to grow at a CAGR of 7.40% from 2022 to 2030[1].

3. Which segment dominates the ophthalmic drugs market? The retinal disorders segment dominates the market, driven by the rising prevalence of age-related macular degeneration and diabetic retinopathy[1].

4. Why is the topical route of administration preferred in ophthalmic drugs? The topical route of administration is preferred due to its targeted delivery and ease of use, particularly for eye drops[1].

5. Which region is expected to exhibit the fastest growth in the ophthalmic drugs market? The Asia Pacific region is expected to exhibit the fastest growth due to advancements in healthcare infrastructure and a large patient pool[1].

Sources

1. Nova One Advisor: Ophthalmic Drugs Market Demand and Growth Analysis with Forecast up to 2030[1].
2. Nova One Advisor: US Ophthalmic Drugs Market Size and Growth[3].
3. Grand View Research: U.S. Ophthalmic Drugs Market Size | Industry Report, 2030[4].

Last updated: 2024-12-30